AG
BLCM

Advisor Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Advisor Group’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$6K Hold
475
– – ﹤0.01% 4613
2019
Q3 		$5K Buy
475
+40
+9% +$523 ﹤0.01% 4695
2019
Q2 		$8K Sell
435
-54
-11% -$1.46K ﹤0.01% 4497
2019
Q1 		$16K Buy
489
+54
+12% +$1.8K ﹤0.01% 4108
2018
Q4 		$13K Sell
435
-380
-47% -$16.9K ﹤0.01% 4077
2018
Q3 		$50K Sell
815
-440
-35% -$29.8K ﹤0.01% 3296
2018
Q2 		$92K Buy
1,255
+575
+85% +$44.8K ﹤0.01% 2593
2018
Q1 		$45K Buy
680
+90
+15% +$6.8K ﹤0.01% 3147
2017
Q4 		$49K Buy
590
+425
+258% +$41.7K ﹤0.01% 3101
2017
Q3 		$20K Buy
165
+36
+28% +$3.79K ﹤0.01% 3569
2017
Q2 		$15K Buy
129
+2
+2% +$248 ﹤0.01% 3700
2017
Q1 		$15K Buy
127
+27
+27% +$3.54K ﹤0.01% 3560
2016
Q4 		$14K Hold
100
– – ﹤0.01% 3467
2016
Q3 		$20K Hold
100
– – ﹤0.01% 3157
2016
Q2 		$12K Buy
+100
New +$11.1K ﹤0.01% 3398

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advisor Group's BLCM Position: Q4 2019 in Review

Advisor Group held its Bellicum Pharmaceuticals, Inc. (BLCM) position steady in Q4 2019 at 475 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #4613.

Advisor Group first reported a position in BLCM in Q2 2016 and has held it in 15 quarters since. The position peaked at $92K in Q2 2018. 51 funds tracked by Wall St. Rank hold BLCM as of Q4 2019.

  • Advisor Group held 475 shares of Bellicum Pharmaceuticals, Inc. worth $6K as of Q4 2019.
  • Advisor Group left its Bellicum Pharmaceuticals, Inc. share count unchanged in Q4 2019.
  • Bellicum Pharmaceuticals, Inc. made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4613 holding.
  • Advisor Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Bellicum Pharmaceuticals, Inc. position peaked at $92K in Q2 2018.
  • 51 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.